High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

Eur Respir J. 2022 Feb 17;59(2):2102930. doi: 10.1183/13993003.02930-2021. Print 2022 Feb.

Abstract

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt

Trial registration: ClinicalTrials.gov NCT04657484.

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • COVID-19*
  • Humans
  • Lung
  • Prednisolone*
  • Respiration, Artificial
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Prednisolone

Associated data

  • ClinicalTrials.gov/NCT04657484